Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …

Immunotherapy includes immune checkpoint inhibitors (ICI) such as antibodies targeting
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death …

B cell and T cell receptor repertoires compose the adaptive immune receptor repertoire
(AIRR) of an individual. The AIRR is a unique collection of antigen-specific receptors that …

Adoptive cell therapy (ACT) has seen a steep rise of new therapeutic approaches in its
immune-oncology pipeline over the last years. This is in great part due to the recent …

The overall efficacy of chimeric antigen receptor modified T cells (CARTs) remain limited in
solid tumors despite intensive studies that aim at targeting multiple antigens, enhancing …

Opinion statement In approximately 15–20% of the patients diagnosed with breast cancer, it
comprises the triple negative (TN) subtype, which until recently lacked targets for specific …

Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …

Abstract Background Regulatory T cells (Tregs) maintain immune tolerance. While Treg-
mediated neuroprotective activities are now well-accepted, the lack of defined antigen …